Hideho Okada, MD, PhD

University of California, San Francisco

As a physician–scientist, Dr. Okada has been dedicated to development of effective immunotherapy for brain tumor patients for over 20 years. His team was one of very first to discover cytotoxic T lymphocyte (CTL) epitopes in glioma-associated and glioma-specific antigens. Dr. Okada has translated these discoveries into a number of innovative immunotherapy clinical studies in both adult and pediatric brain tumor patients, including multicenter vaccine trials. To improve radiologic evaluation criteria for brain tumor patients undergoing immunotherapy, Dr. Okada leads an international group of brain tumor immunotherapy experts to develop novel iRANO criteria.